Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
mils™ - nsclc (1 trial)
pembrolizumab (keytruda) (2 trials)
activated marrow infiltrating lymphocytes (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Lung Neoplasms (Phase 2)
Neoplasms (Phase 2)
Trials (2 total)
Trial APIs (3 total)